Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Pettaway, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Pettaway, C. A.
Clinical Cancer Research Vol. 9, 2185-2194, June 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy1

Hiroki Kuniyasu, Rinzo Ukai, Dennis Johnston, Patricia Troncoso, Isaiah J. Fidler and Curtis A. Pettaway2

Department of Oncological Pathology, Cancer Center, Nara Medical University, Kashihara, Japan [H. K.]; JR Hiroshima General Hospital of West Japan Railway Company, Hiroshima, Japan [R. U.]; and the Departments of Biomathematics [D. J.], Pathology [P. T.], Cancer Biology and [I. J. F., C. A. P.], and Urology [C. A. P.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: To determine whether the expression ratio of matrix metalloproteinase (MMP) to E-cadherin mRNA (MMP:E-cadherin) in biopsy (BX) samples of prostate cancer correlate with that of radical prostatectomy (RP) specimens and assists in predicting pathologic stage.

Experimental Design: The mRNA expression levels for MMP-2 and -9 and of E-cadherin were determined by a colorimetric in situ hybridization assay in 44 paired BX and RP specimens. Clinical stage, BX Gleason score (GS), total length of cancer in BX cores, and serum prostate-specific antigen levels were also assessed.

Results: Clinical stage was confined in 39 of 44 (89%) patients. Subsequent to RP, however, only 17 of 44 (39%) patients had proven organ-confined disease (pT2). BX GSs agreed with the RP GS in 77% of RP specimens. We found a strong correlation between BX and RP MMP:E-cadherin ratios (correlation coefficient = 0.755). The ratio increased as the GS increased and pathologic stage advanced (pT2 versus ≥ pT3). Increasing clinical stage, GS, and serum prostate-specific antigen were significantly associated with advanced cancer at RP (P = 0.004–0.0001). The BX MMP:E-cadherin ratio, however, exhibited the strongest association with pathologic stage and independently predicted the status of 89% of the RP cases based on a BX ratio of <6 (predicted stage pT2 cancer at RP) versus ≥6 (predicted stage ≥ pT3 at RP).

Conclusion: The BX MMP:E-cadherin ratio represents a novel prognostic assay for predicting stage of cancer at RP. These data provide proof of principle for directly assessing the biological potential of prostate cancer using molecular strategies in patient’s specimens.




This article has been cited by other articles:


Home page
Cancer Res.Home page
T. Hara, H. Miyazaki, A. Lee, C. P. Tran, and R. E. Reiter
Androgen Receptor and Invasion in Prostate Cancer
Cancer Res., February 15, 2008; 68(4): 1128 - 1135.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Myoishi, H. Hao, T. Minamino, K. Watanabe, K. Nishihira, K. Hatakeyama, Y. Asada, K.-i. Okada, H. Ishibashi-Ueda, G. Gabbiani, et al.
Increased Endoplasmic Reticulum Stress in Atherosclerotic Plaques Associated With Acute Coronary Syndrome
Circulation, September 11, 2007; 116(11): 1226 - 1233.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Efstathiou, P. Troncoso, S. Wen, K.-A. Do, C. A. Pettaway, L. L. Pisters, T. J. McDonnell, and C. J. Logothetis
Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1224 - 1231.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Zi, Y. Guo, A. R. Simoneau, C. Hope, J. Xie, R. F. Holcombe, and B. H. Hoang
Expression of Frzb/Secreted Frizzled-Related Protein 3, a Secreted Wnt Antagonist, in Human Androgen-Independent Prostate Cancer PC-3 Cells Suppresses Tumor Growth and Cellular Invasiveness
Cancer Res., November 1, 2005; 65(21): 9762 - 9770.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. J. Assikis, K.-A. Do, S. Wen, X. Wang, J. H. Cho-Vega, S. Brisbay, R. Lopez, C. J. Logothetis, P. Troncoso, C. N. Papandreou, et al.
Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential
Clin. Cancer Res., October 15, 2004; 10(20): 6770 - 6778.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.